These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1276 related articles for article (PubMed ID: 32025828)

  • 61. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia.
    Thomas X; Paubelle E
    Expert Opin Biol Ther; 2018 Nov; 18(11):1095-1106. PubMed ID: 30296188
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Not Available].
    Dourthe MÉ; Yakouben K; Chaillou D; Lesprit E; Dalle JH; Baruchel A
    Bull Cancer; 2018 Dec; 105 Suppl 2():S147-S157. PubMed ID: 30686353
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.
    Jacoby E; Bielorai B; Avigdor A; Itzhaki O; Hutt D; Nussboim V; Meir A; Kubi A; Levy M; Zikich D; Zeltzer LA; Brezinger K; Schachter J; Nagler A; Besser MJ; Toren A
    Am J Hematol; 2018 Dec; 93(12):1485-1492. PubMed ID: 30187944
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia.
    Ceppi F; Gardner RA
    Cancer J; 2019; 25(3):191-198. PubMed ID: 31135526
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Recent updates on CAR T clinical trials for multiple myeloma.
    Lin Q; Zhao J; Song Y; Liu D
    Mol Cancer; 2019 Nov; 18(1):154. PubMed ID: 31684964
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study.
    Jacoby E; Ghorashian S; Vormoor B; De Moerloose B; Bodmer N; Molostova O; Yanir AD; Buechner J; Elhasid R; Bielorai B; Rogosic S; Dourthe ME; Maschan M; Rossig C; Toren A; von Stackelberg A; Locatelli F; Bader P; Zimmermann M; Bourquin JP; Baruchel A
    Leukemia; 2022 Jun; 36(6):1525-1532. PubMed ID: 35468946
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
    Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
    Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
    Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
    Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
    [TBL] [Abstract][Full Text] [Related]  

  • 70. At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.
    Oluwole OO; Davila ML
    J Leukoc Biol; 2016 Dec; 100(6):1265-1272. PubMed ID: 27354412
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
    Kebriaei P; Singh H; Huls MH; Figliola MJ; Bassett R; Olivares S; Jena B; Dawson MJ; Kumaresan PR; Su S; Maiti S; Dai J; Moriarity B; Forget MA; Senyukov V; Orozco A; Liu T; McCarty J; Jackson RN; Moyes JS; Rondon G; Qazilbash M; Ciurea S; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Kantarjian H; Keating M; Wierda W; Do KA; Largaespada DA; Lee DA; Hackett PB; Champlin RE; Cooper LJ
    J Clin Invest; 2016 Sep; 126(9):3363-76. PubMed ID: 27482888
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies.
    Cao JX; Gao WJ; You J; Wu LH; Liu JL; Wang ZX
    Cytotherapy; 2019 Jul; 21(7):769-781. PubMed ID: 31160157
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
    Kochenderfer JN; Rosenberg SA
    Nat Rev Clin Oncol; 2013 May; 10(5):267-76. PubMed ID: 23546520
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.
    Itzhaki O; Jacoby E; Nissani A; Levi M; Nagler A; Kubi A; Brezinger K; Brayer H; Zeltzer LA; Rozenbaum M; Vernitsky H; Markel G; Toren A; Avigdor A; Schachter J; Besser MJ
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152221
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
    Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
    [TBL] [Abstract][Full Text] [Related]  

  • 77. CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.
    Davila ML; Kloss CC; Gunset G; Sadelain M
    PLoS One; 2013; 8(4):e61338. PubMed ID: 23585892
    [TBL] [Abstract][Full Text] [Related]  

  • 78. CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report.
    Wen S; Niu Z; Xing L; Wang Y; Li H; Kuang N; Luo J; Zhang X; Wang F
    BMC Cancer; 2018 Nov; 18(1):1143. PubMed ID: 30458755
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
    Gupta S; Kohorst M; Alkhateeb HB
    Eur J Haematol; 2024 Jan; 112(1):51-63. PubMed ID: 38105391
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Managing the toxicities of CAR T-cell therapy.
    Neelapu SS
    Hematol Oncol; 2019 Jun; 37 Suppl 1():48-52. PubMed ID: 31187535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 64.